Ons wil graag hê dat jy deel word van ons gemeenskap. Sluit aan by ons Discord om met ons en ander lede te skakel!

Ticker
FAGR.BR

Price
18.12
Stock movement down
-0.12 (-0.66%)
Company name
Fagron NV
Exchange
(BR
,
Currency
EUR
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Markkapitalisasie
1.32B
Ondernemingswaarde
1.79B
Prys/Verkope
1.11
Prys/Boek
2.77
Dividendopbrengs
-
Dividendgroei
-
Groei jare
-
FCF uitbetaling
39.87%
Agterlopende P/E
11.89
Volgende P/E
14.02
PEG
-
EPS groei
10.36%
1 jaar opbrengs
8.31%
3 jaar opbrengs
4.74%
5 jaar opbrengs
-2.48%
10 jaar opbrengs
-5.49%
Laaste opgedateer: 2024-12-21

DIVIDENDE

FAGR.BR betaal nie dividende nie of geen data is ontvang nie

WAARDERING

Waarderingsverhoudings

Loading...
Waarderingsverhoudings gegewens
Agterlopende P/E11.89
Prys tot OCF7.72
Prys tot FCF13.02
Prys tot EBITDA5.07
EV tot EBITDA6.88

Waardering (Verkope/Boekwaarde)

Loading...
Waardering (Verkope/Boekwaarde) gegewens
Prys tot verkope1.11
Prys tot Boekwaarde2.77
EV tot verkope1.50

FINANSIËLE

Per aandeel

Loading...
Per aandeel gegewens
Huidige aandeeltelling72.84M
EPS (TTM)1.52
FCF per aandeel (TTM)1.39

Inkomstestaat

Loading...
Inkomstestaat gegewens
Inkomste (TTM)1.19B
Bruto wins (TTM)246.81M
Bedryfsinkomste (TTM)173.29M
Netto inkomste (TTM)110.97M
EPS (TTM)1.52
EPS (1j vorentoe)1.29

Marges

Loading...
Marges gegewens
Bruto marge (TTM)20.70%
Bedryfsmarge (TTM)14.53%
Winsgrens (TTM)9.31%

Balansstaat

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Balansstaat gegewens
Kontant96.69M
Netto debiteure86.62M
Totale bedryfsbates348.24M
Klandisiewaarde448.22M
Ontasbare bates48.54M
Eiendom, aanleg en toerusting0.00
Totale bates1.05B
Rekeninge betaalbaar117.11M
Kort/huidige langtermynskuld362.76M
Totale bedryfslaste200.47M
Totale laste567.95M
Aandeelhouersbelang477.11M
Netto tasbare bates0.00

Kontantvloei

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Kontantvloei gegewens
Bedryfskontantvloei (TTM)170.95M
Kapitale uitgawes (TTM)69.55M
Vrye kontantvloei (TTM)101.40M
Dividende betaal (TTM)40.43M

Finansiële opbrengste

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Finansiële opbrengste gegewens
Opbrengs op ekwiteit23.26%
Opbrengs op bates10.62%
Opbrengs op belegde kapitaal23.19%
Kontant opbrengs op belegde kapitaal21.19%

AANDELE INLIGTING

Aandele grafiek

Loading...
Aandele prys data
Open18.40
Daaglikse hoog18.40
Daaglikse laag18.12
Daaglikse volume229K
Hoogtepunt van alle tye41.63
1j analiseraaming22.24
Beta0.26
EPS (TTM)1.52
Dividend per aandeel-
Ex-dividend datum21 May 2024
Volgende verdienste datum13 Feb 2025

Afwaartse potensiaal

Loading...
Afwaartse potensiaal gegewens
FAGR.BRS&P500
Huidige prysdaling vanaf die hoogste punt van alle tye-56.48%-2.74%
Hoogste prysdaling-90.66%-56.47%
Datum van hoogste daling14 Dec 20159 Mar 2009
Gemiddelde daling vanaf hoogtepunt-40.49%-11.13%
Gemiddelde tyd tot nuwe hoogtepunt39 days12 days
Maksimum tyd tot nuwe hoogtepunt2659 days1805 days
MAATSKAPPY BESONDERHEDE
FAGR.BR (Fagron NV) company logo
Markkapitalisasie
1.32B
Markkapitalisasie kategorie
Small-cap
Beskrywing
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Werknemers
3647
Beleggerverhoudings
-
CEO
Land
Belgium
Stad
Aandele tipe
-
CCC status
-
Dividendfrekwensie
-
GEBEURE EN AANBIEDINGS
GebeureAanbiedings
Loading...
VERSTAAN DIE BESIGHEID
Loading...
MAATSKAPPY NUUS
Alle nuusPersvrystellings
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET Disclosure of notification received from FMR LLC Pursuant to the Belgian law of 2 May 2007 regardin...
26 November 2024
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue gro...
10 Oktober 2024
Fagron SA (ARSUF) reports robust revenue growth and improved margins, with significant gains in North America and an optimistic outlook for the full year.
9 Oktober 2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024 – 9:00 PM CET Disclosure of notification received from AOC Pharma S.à r.l. Pursuant to the Belgian law of 2 May 200...
8 Oktober 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program to...
13 September 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 September 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 2 September 2024 through 6 September 2...
6 September 2024
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REB...
1 Augustus 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutic...
13 Mei 2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board o...
12 April 2024
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagr...
11 April 2024
Volgende bladsy